跳至主要内容
临床试验/ISRCTN12572202
ISRCTN12572202进行中(未招募)未知

A MULTI-centre feasibility study to assess the use of 99m Tc-SestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study)

niversity College London0 个研究点目标入组 150 人开始时间: 2022年5月5日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
150

研究概览

简要总结

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36693694/ (added 25/01/2023)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age >18 years, and <95 years of age
  • 2. Any gender
  • 3. cT1 renal tumour >2cm identified on cross sectional imaging (CT or MRI) of unknown histological diagnosis
  • 4. Patients undergoing tumour biopsy or surgery as part of routine care
  • 5. Willing and able to provide informed consent.

排除标准

  • 1. Females who are pregnant, planning pregnancy or breastfeeding
  • 2. Concurrent and/or recent involvement in other research that is likely to interfere with the intervention within 3 months of study enrolment
  • 3. Multiple comorbidities which would make trial participation difficult (e.g. burden of an additional hospital visit).
  • 4. Allergy to 99mTc Sestamibi

研究者

发起方
niversity College London

相似试验